Locations:
Search
Observational evidence of neuroprotection with GLP-1 receptor agonists and SGLT-2 inhibitors
Study is first to show reduction in autoimmune disease with the common diabetes and obesity drugs
Surgical intervention linked to increased lifespan and reduced complications
Evidence mounts that these diabetes and obesity drugs may protect eyes, not endanger them
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Use of GLP-1s and improving cardiovascular health lowers risk of hematologic malignancies
Complications highlight need to exercise caution when managing geriatric patients
Findings show greater reduction in CKD progression, kidney failure than GLP-1RAs
Provider vigilance and patient education are key for management
Findings establish overweight/obesity as a modifiable risk factor for cardiovascular disease
Two major trials promise key progress against the last unaddressed major risk factor
Advertisement
Advertisement